Atea Pharmaceuticals Reports $45.4 Million Net Loss in Q1 2026, Increases R&D Spending

Atea Pharmaceuticals, Inc. reported a net loss of $45.4 million for the first quarter of 2026, compared to a net loss of $34.3 million for the same period in 2025, reflecting an increase of $11.2 million year-over-year. The company's total operating expenses rose to $48.0 million, up from $39.0 million in the prior year, primarily driven by increased research and development costs associated with its Phase 3 clinical trials for hepatitis C virus (HCV) treatment. Research and development expenses surged to $41.1 million, a significant increase from $29.6 million in the previous year, while general and administrative expenses decreased to $6.9 million from $9.5 million.

As of March 31, 2026, Atea's total assets were reported at $267.1 million, down from $315.2 million at the end of 2025. The decline in assets was largely attributed to a decrease in cash and cash equivalents, which fell to $79.3 million from $95.7 million. Marketable securities also decreased to $176.7 million from $206.1 million. The company's total stockholders' equity decreased to $233.7 million from $275.4 million, primarily due to the net loss incurred during the quarter.

Strategically, Atea is advancing its lead product candidate, a regimen of bemnifosbuvir and ruzasvir, which is currently in Phase 3 clinical development for HCV. The C-BEYOND trial is fully enrolled with over 880 patients, and topline results are expected in mid-2026. The company is also preparing to initiate a Phase 1 clinical trial for AT-587, a candidate for hepatitis E virus (HEV), anticipated to start in mid-2026. Atea has entered into a license agreement with Merck for ruzasvir, which includes milestone payments and royalties based on future sales.

In terms of operational metrics, Atea's workforce was reduced by approximately 25% in early 2025, a move expected to save around $15 million through 2027. The company has not generated any product revenue since its inception and does not anticipate doing so in the near future. Atea's liquidity position remains strong, with $256.0 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which the company believes will fund operations through at least 2027. However, the company acknowledges the need for additional capital to support ongoing clinical trials and potential commercialization efforts, indicating that future financing may be necessary to sustain its operations and development plans.